Skip to main content
. 2021 Nov 22;6(22):e150999. doi: 10.1172/jci.insight.150999

Figure 2. Circulating PR3+ B cells and PR3-ANCA production in patients with PR3-AAV and MPO-AAV and HCs.

Figure 2

Representative examples of the gating of PR3+ B cells among total CD19+ cells in a patient with PR3-AAV, a patient with MPO-AAV, and a HC (A). PR3+ B cell frequency and count were increased in patients with PR3-AAV (n = 105) compared with patients with MPO-AAV (n = 49) and HCs (n = 27) (B and C). PBMCs were cultured to promote differentiation into antibody-secreting cells, after which PR3-ANCA secretion was analyzed by means of a Phadia ImmunoCAP 250 analyzer (D). Only patients with PR3-AAV can produce PR3-ANCA IgG in vitro. Correlation of circulating (in vivo) PR3-ANCA IgG with secreted (in vitro) PR3-ANCA IgG in patients with PR3-AAV (E). Data represent median (25%–75% IQR). Multiple comparisons among more than 2 groups were performed with Kruskal-Wallis test. *P < 0.05, ***P < 0.001 after correction for FDR with Benjamini and Hochberg test.